Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries
The Journal of Infection in Developing Countries · 2025
DOI: 10.3855/jidc.19914 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Branko Beronja und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antibodies, Monoclonal, Humanized, Treatment Delay, Developing Countries. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
During the coronavirus disease 2019 (COVID-19) pandemic, low- and middle- income countries had less access to monoclonal antibodies, such as tocilizumab (TCZ), compared to high-income countries. This retrospective cohort study aimed at evaluating the impact of a delayed TCZ administration on patient outcomes, and at determining the optimum timing of TCZ initiation for COVID-19 pneumonia in Serbia. Methodology: The study included 150 patients who received TCZ at a tertiary referral center. The outcomes analyzed in this study were the need for an intensive care unit (ICU) treatment and mortality.
Results
The multiple Cox proportional hazard model suggested that the delay in TCZ administration was an independent predictor of needing ICU treatment and mortality. The receiver operating characteristic (ROC) curve showed that patients who received TCZ after 7.5 days since the onset of symptoms had 74.4% higher chances of needing ICU treatment. Receiving TCZ after 9.5 days since the onset of symptoms, increased the chances of mortality by 78.9%. The multiple Cox proportional hazard model suggested that TCZ administration after 7.5 days since the onset of symptoms increased the hazard for ICU admission by 24.5%; and the hazard of mortality increased by 46.1% after 9.5 days since the onset of symptoms.
Conclusions
This study emphasizes the importance of timely administration of TCZ in COVID-19 pneumonia. Better outcomes were observed when TCZ was administered up to 7.5 days since the onset of symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, Belgrade, Serbia.
- Clinic for Lung Diseases, Clinical Center of Serbia, Belgrade, Serbia.
Zitieren
APA
Beronja, B., Stevanović, O., Nikolić, N., Mitrović, N., Gazibara, T., Todorović, N., Filipović, A., Dotlic, J., Stjepanović, M., Simić, J., & Milosevic, I. (2025). Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19914
Vancouver
Beronja B, Stevanović O, Nikolić N, Mitrović N, Gazibara T, Todorović N, et al. Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.19914
BibTeX
@article{Beronja2025,
author = {Beronja, Branko and Stevanović, Olja and Nikolić, Nataša and Mitrović, Nikola and Gazibara, Tatjana and Todorović, Nevena and Filipović, Ana and Dotlic, Jelena and Stjepanović, Mihailo and Simić, Jelena and Milosevic, Ivana},
title = {Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries},
journal = {The Journal of Infection in Developing Countries},
year = {2025},
doi = {10.3855/jidc.19914}
}
EUVIMED